Aggrifib Injection

Introduction

Aggrifib is a medication that contains the active ingredient Tirofiban. It is available in injectable form and is primarily used for the treatment of certain heart conditions.

Uses

Aggrifib is prescribed to patients who have undergone certain procedures, such as angioplasty or stent placement, to open up blocked arteries in the heart. It is used to prevent blood clots from forming in these arteries and causing further complications.

Dosage and Administration

The dosage of Aggrifib will be determined by your healthcare provider based on your specific medical condition. It is usually administered as an intravenous (IV) infusion over a period of time. The duration and frequency of the treatment will depend on the individual patient’s needs.

Mechanism of Action

Tirofiban, the active ingredient in Aggrifib, belongs to a class of medications known as antiplatelet agents. It works by preventing the formation of blood clots in the arteries by inhibiting the activation of platelets, which are small cells that play a key role in blood clotting.

Side Effects

Common side effects may include bleeding, bruising, or pain at the injection site. Serious side effects, although rare, may include severe bleeding, allergic reactions, or a decrease in platelet count. If you experience any of these serious side effects, seek immediate medical attention.

Drug Interactions

Aggrifib may interact with other medications, s. Inform your healthcare provider about all the medications you are currently taking. Some medications, such as anticoagulants or other antiplatelet agents, may increase the risk of bleeding when used in combination with Aggrifib. Your healthcare provider will carefully consider these potential interactions when prescribing this medication.

Precautions

There are certain precautions that should be taken when using Aggrifib. Inform your healthcare provider if you have a history of bleeding disorders, recent surgery, or any other medical conditions that may increase the risk of bleeding. Additionally, avoid activities that may increase the risk of injury or bleeding while using this medication.

Storage

Aggrifib should be stored according to the manufacturer’s instructions. It is typically recommended to store the medication at room temperature, away from excessive heat, moisture, and direct light. Keep this medication out of the reach of children and pets.

Patient Tips

Here are some additional tips to keep in mind when using Aggrifib:

• Follow the dosage and administration instructions provided by your healthcare provider.
• If you miss a dose, contact your healthcare provider for further guidance.
• Inform your healthcare provider about any other medications, including over-the-counter drugs and supplements, that you are taking.
• If you experience any unusual bleeding, bruising, or other side effects, contact your healthcare provider immediately.
• Attend all follow-up appointments with your healthcare provider to monitor your progress and adjust the treatment if needed.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Aggrastat 250 mcg/ml Concentrate for Solution for Infusion (Health Professionals SmPC) Available at:
• Tirofiban (Drugs.com) [Accessed 21 Jun. 2024] (online) Available at:
• Enoxaparin Injection (MedlinePlus) [Accessed 1 Jun. 2024] (online) Available at:
• Zi W, Song J, Kong W, Huang J, Guo C, He W, Yu Y, Zhang B, Geng W, Tan X, Tian Y, Liu Z, Cao M, Cheng D, Li B, Huang W, Liu J, Wang P, Yu Z, Liang H, Yang S, Tang M, Liu W, Huang X, Liu S, Tang Y, Wu Y, Yao L, Shi Z, He P, Zhao H, Chen Z, Luo J, Wan Y, Shi Q, Wang M, Yang D, Chen X, Huang F, Mu J, Li H, Li Z, Zheng J, Xie S, Cai T, Peng Y, Xie W, Qiu Z, Liu C, Yue C, Li L, Tian Y, Yang D, Miao J, Yang J, Hu J, Nogueira RG, Wang D, Saver JL, Li F, Yang Q; RESCUE BT2 Investigators. Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion. N Engl J Med. 2023 Jun 1;388(22):2025-2036. doi: 10.1056/NEJMoa2214299. [Accessed 30 Jun. 2024] Available at: